A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Mitotech

Status and phase: Completed; Phase 2

Conditions: Keratoconjunctivitis Sicca

Treatments: Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution; Drug: Placebo (Vehicle) opthalmic solution; Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution

Study type: Interventional

Funder types: Industry

Identifiers

NCT02121301

13-110-0006

Details and patient eligibility

About

The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.

Full description

Single-center, double-masked, randomized, placebo-controlled study comprising 4 visits over the course of approximately 5 weeks. The study included a 1-week placebo (SkQ1 vehicle) run-in period between Visit 1 and Visit 2, and approximately 28 days of twice daily (BID) dosing (Visit 2 - Visit 4). Qualified subjects were randomized 1:1:1 to receive either 1.55 µg/mL SkQ1 ophthalmic solution, 0.155 µg/mL SkQ1 ophthalmic solution, or placebo (vehicle of SkQ1 ophthalmic solution).

The following primary endpoints were tested:

• Corneal Fluorescein staining in the inferior region Pre-CAE at Visit 4 (Day 29), as measured by the Ora Calibra Scale in the worst eye at baseline;
• Worst dry eye symptom (ocular discomfort, dryness, or grittiness - as determined from subject diary data recorded during the 1-week run-in period between Visit 1 and Visit 2) evaluated over the seven days preceding Visit 4 (not including day of visit) during the treatment period.

Enrollment: 91 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Be male or female of any race, at least 18 years of age
• Have provided written informed consent
• Have a reported history of dry eye syndrome
• Have a history of use or desire to use eye drops for dry eye

Exclusion criteria

• Have any clinically significant eye findings that require therapeutic treatment or may interfere with study parameters
• Have previously had LASIK surgery within the last 12 months
• Have used Restasis® within 30 days of Visit 1
• Be a woman who is pregnant, nursing or planning a pregnancy
• Be unwilling to submit a urine pregnancy test if of childbearing potential
• Have a known allergy and/or sensitivity to the test article or its components, including the preservative benzalkonium chloride
• Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1
• Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

91 participants in 3 patient groups, including a placebo group

Low Dose SkQ1

Experimental group

Description:

Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days

Treatment:

Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution

High Dose SkQ1

Experimental group

Description:

Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days

Treatment:

Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution

Placebo (vehicle)

Placebo Comparator group

Description:

Drug: Placebo (vehicle) ophthalmic solution administered twice daily for 28 days

Treatment:

Drug: Placebo (Vehicle) opthalmic solution